Pair Name	Sulforaphane, Gefitinib
Disease Info	[ICD-11: 2C25]	Lung cancer		Investigative
Gene Regulation	Down-regulation	Phosphorylation	AKT1	hsa207
	Up-regulation	Expression	CDH1	hsa999
	Down-regulation	Expression	CDH2	hsa1000
	Up-regulation	Expression	CLDN1	hsa9076
	Down-regulation	Phosphorylation	EGFR	hsa1956
	Down-regulation	Phosphorylation	MAPK1	hsa5594
	Down-regulation	Expression	VIM	hsa7431
In Vitro Model	PC-9	Lung adenocarcinoma	Homo sapiens (Human)	CVCL_B260
Result	SFN overcame T790M-mediated gefitinib resistance in vitro through EMT. Thus, a combination of gefitinib and SFN may be a beneficial treatment strategy for lung cancer patients with acquired resistance due to T790M mutation.

Pair Name	Sulforaphane, Gefitinib
Disease Info	[ICD-11: 2C25]	Lung cancer		Investigative
Gene Regulation	Down-regulation	Expression	CD44	hsa960
	Down-regulation	Expression	GLI1	hsa2735
	Down-regulation	Expression	GLI2	hsa2736
	Down-regulation	Expression	PROM1	hsa8842
	Down-regulation	Expression	SHH	hsa6469
	Down-regulation	Expression	SMO	hsa6608
In Vitro Model	PC-9	Lung adenocarcinoma	Homo sapiens (Human)	CVCL_B260
Result	The results of the present study demonstrated that SFN inhibits the proliferation of gefitinib-tolerant lung cancer cells via modulation of the SHH signaling pathway. Therefore, combined SFN and gefitinib therapy may be an effective approach for the treatment of lung cancer.